학술논문
Identification of Tools to Measure Changes in Musculoskeletal Symptoms and Physical Functioning in Women With Breast Cancer Receiving Aromatase Inhibitors.
Document Type
Article
Author
Source
Subject
*AROMATASE inhibitors
*BREAST tumors
*CHI-squared test
*GRIP strength
*LONGITUDINAL method
*MUSCULOSKELETAL system diseases
*QUESTIONNAIRES
*RESEARCH funding
*SELF-evaluation
*T-test (Statistics)
*SAMPLE size (Statistics)
*EFFECT sizes (Statistics)
*PAIN measurement
*BODY mass index
*SEVERITY of illness index
*POSTMENOPAUSE
*DATA analysis software
*FUNCTIONAL assessment
*DESCRIPTIVE statistics
*SYMPTOMS
*THERAPEUTICS
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
0190-535X
Abstract
Purpose/Objectives: To estimate and compare responsiveness of standardized self-reported measures of musculoskeletal symptoms (MSSs) and physical functioning (PF) during treatment with aromatase inhibitors (AIs).Design: Prospective, longitudinal study.Setting: Park Nicollet Institute and North Memorial Cancer Center, both in Minneapolis, MN.Sample: 122 postmenopausal women with hormone receptor-positive breast cancer.Methods: MSSs and PF were assessed before starting AIs and at one, three, and six months using six self-reported MSSs measures and two PF tests.Main Research Variables: MSSs and PF changes from baseline to six months.Findings: Using the Breast Cancer Prevention Trial-Musculoskeletal Symptom (BCPT-MS) subscale, 54% of participants reported MSSs by six months. Scores from the BCPT-MS subscale and the physical function subscales of the Australian/Canadian Osteoarthritis Hand Index (AUSCAN) and Western Ontario and McMaster Osteoarthritis Index (WOMAC) were most responsive to changes over six months.Conclusions: BCPT-MS, AUSCAN, and WOMAC were the most responsive instruments for measuring AI-associated MSSs.Implications for Nursing: Assessment and management of MSSs are important aspects of oncology care because MSSs can affect functional ability and AI adherence.Knowledge Translation: The three measures with the greatest sensitivity were the BCPT-MS, AUSCAN, and WOMAC questionnaires. These measures will be useful when conducting research on change in MSSs associated with AI treatment in women with breast cancer. [ABSTRACT FROM AUTHOR]